This protocol addresses monomicrobial actinomycosis of severe extent in the abdomen — defined as life-threatening involvement of an organ or simultaneous involvement of multiple organs — in a patient without penicillin allergy.
Severe disease is distinguished from mild monomicrobial abdominal actinomycosis specifically by the degree of organ compromise: single-organ life-threatening disease or multi-organ involvement meets the threshold for this treatment approach.
Severe monomicrobial abdominal actinomycosis without penicillin allergy is managed with an intravenous penicillin-based antibiotic regimen; the complete structured protocol — including the full agent selection, dosing guidance, and sequencing — is available via the link below.
Treatment goal: Resolution of the actinomycosis infection, typically requiring an extended course of antimicrobial therapy.
DOI: 10.5772/intechopen.104698
For patients with monomicrobial infections, treatment can be divided base on mild versuss severe disease.
If the infection involves an organ causing a life threatening disease or multiple organs, it is considered severe.
For severe infection, initial course of 10 to 20 million units daily of intravenous penicillin G (divided into four to six hours) is recommended.
Antimicrobial treatment should be continued until resolution of infection, usually between 6 and 12 months.
View source ↗